When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
ALXN - Is AstraZeneca Paying Too Much for Alexion?
Alexion Pharmaceuticals Inc.
Earlier this month, AstraZeneca (NASDAQ: AZN) announced plans to acquire rare-disease expert Alexion (NASDAQ: ALXN) for $39 billion. In this video from Motley Fool Live, recorded on Dec. 14, Corinne Cardina, bureau chief of healthcare and cannabis, and Fool.com contributor Brian Orelli discuss what AstraZeneca is getting in the deal. They also debate whether the U.K.-based drugmaker is overpaying for access to Alexion's repertory of commercial drugs and drug candidates.